Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs GameStop Corp. (GME) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade
GameStop Corp.Trade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs GameStop Corp. — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $357.04 (market cap $9.43B), while GameStop Corp. trades at $18.64 (market cap $8.44B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock and GameStop Corp. are close in size by market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, GameStop Corp. nearer its low. Which is the better fit depends on your goals.

BIOGME
Market Cap
$9.43B$8.44B
Sector
HealthConsumer Cyclical
52-Week High
$356.25$27.69
52-Week Low
$241.71$18.79
Enterprise Value
$9.18B$4.42B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories (BIO) trades at $351.10, down 0.97% on the day but maintaining strength near its 52-week high. The stock shows bullish technical momentum with strong moving average support and recently beat Q2 2026 earnings estimates with $2.62 EPS versus $1.75 expected. Fundamentals show improving profitability with 29.41% net margin in 2025, though revenue remains flat at $2.6 billion. Analyst consensus remains positive with 7 buy ratings and $350 price target.

BIO presents a mixed outlook with strong technical momentum and improving profitability offset by flat revenue growth and elevated valuation multiples. The stock's current price aligns with analyst consensus target, suggesting limited near-term upside. Key risks include academic research market softness and competitive pressures in life science instruments. Institutional ownership trends show continued confidence with recent position increases by major funds.

GameStop Corp.

GME trades at $18.57, down 1.2% with bearish technical signals from moving averages. The company shows improving fundamentals with three consecutive quarterly earnings beats and a significant turnaround to profitability, achieving a 20.45% net income margin in 2025. Recent news highlights strategic shifts including potential partnership discussions with eBay instead of a full acquisition. Cash position strengthened to $4.77 billion following a $3.85 billion net cash inflow in 2025.

The outlook remains mixed with strong profitability improvements offset by bearish technical indicators and cautious analyst sentiment. Investment opportunity exists in the company's operational turnaround and cash-rich balance sheet, while risks include potential shareholder dilution from recent debt conversions and ongoing competitive pressures in the retail gaming sector.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO

About GameStop Corp.

Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.

Read more on GME